Login / Signup

Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis.

Yareth Gopar-CuevasAna P Duarte-JuradoRosa N Diaz-PerezOdila Saucedo-CárdenasMaría de Jesús Loera AriasRoberto Montes de Oca-LunaHumberto Rodríguez-RochaAracely Garcia-Garcia
Published in: Molecular neurobiology (2021)
Parkinson's disease (PD) ranks first in the world as a neurodegenerative movement disorder and occurs most commonly in an idiopathic form. PD patients may have motor symptoms, non-motor symptoms, including cognitive and behavioral changes, and symptoms related to autonomic nervous system (ANS) failures, such as gastrointestinal, urinary, and cardiovascular symptoms. Unfortunately, the diagnostic accuracy of PD by general neurologists is relatively low. Currently, there is no objective molecular or biochemical test for PD; its diagnosis is based on clinical criteria, mainly by cardinal motor symptoms, which manifest when patients have lost about 60-80% of dopaminergic neurons. Therefore, it is urgent to establish a panel of biomarkers for the early and accurate diagnosis of PD. Once the disease is accurately diagnosed, it may be easier to unravel idiopathic PD's pathogenesis, and ultimately, finding a cure. This review discusses several biomarkers' potential to set a panel for early idiopathic PD diagnosis and future directions.
Keyphrases